Caydan Portfolio Company MitoSense Secures Japanese Patent for Mitochondria-Based Therapy for Neurodegenerative Diseases

Plymouth, MA – Caydan Capital Partners announced today that its portfolio company, MitoSense Inc., a pioneering biotechnology company specializing in mitochondria-based therapeutics, has been granted a Japanese patent (Patent No. 7617652) for its innovative approach to treating neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This milestone underscores MitoSense’s commitment to revolutionizing medical treatments for neurodegenerative disorders through its proprietary Mitochondria Organelle Transplantation (MOT™) technology.

‍

The newly granted Japanese patent, titled "Compositions and Methods for the Treatment of ALS and Other Neurodegenerative Diseases," covers the company’s cutting-edge methodology of isolating and transplanting healthy mitochondria from donor cells into patients suffering from mitochondrial dysfunction. This breakthrough therapy aims to restore cellular energy production and mitigate disease progression, offering a novel and potentially transformative treatment for patients worldwide.

‍

"Securing this patent in Japan represents a significant step forward for MitoSense as we continue to expand the global reach of our proprietary MOT technology," said Van Hipp, Chairman of MitoSense. "With neurodegenerative diseases affecting over 55 million people worldwide, including approximately 200,000 individuals suffering from ALS globally, our innovative approach has the potential to change lives by addressing mitochondrial dysfunction at its core."

‍

The Japanese patent builds upon MitoSense’s growing intellectual property portfolio, complementing its recently secured U.S. patent for the same technology. As a leader in mitochondrial research and therapeutics, MitoSense continues to advance clinical development and strategic partnerships to bring this groundbreaking treatment to patients in need.

‍

With this patent protection, MitoSense is poised to explore collaborations with leading Japanese research institutions and pharmaceutical companies to accelerate the clinical application of its mitochondrial transplantation technology in the region. This milestone strengthens MitoSense’s position as an innovator in regenerative medicine and underscores the company’s commitment to developing novel therapies for neurodegenerative diseases.

‍

About MitoSense Inc.

For more information on MitoSense Inc. and its groundbreaking research, please visit www.mitosense.com.

‍

About Caydan Capital Partners

Caydan Capital Partners is a Boston, Massachusetts-based private equity firm focused on control investments in growth-oriented companies in the North American lower middle market. With offices in Boston, Dallas, and Puerto Rico, Caydan provides investors with access to a historically less accessible segment of the market through a diversified investment platform spanning private equity, public equity, and venture capital. For more information, please visit https://www.caydancapital.com/.

‍